174 related articles for article (PubMed ID: 3111667)
41. Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment.
Lund B; Storm TL; Lund B; Melsen F; Mosekilde L; Andersen RB; Egmose C; Sørensen OH
Clin Rheumatol; 1985 Jun; 4(2):143-9. PubMed ID: 4006384
[TBL] [Abstract][Full Text] [Related]
42. A randomized study comparing deflazacort and prednisone in heart transplant patients.
Arizón JM; Anguita M; Vallés F; López-Rubio F; López-Granados A; Casares J; Segura J; Mesa D; Muñoz I; Alados P
J Heart Lung Transplant; 1993; 12(5):864-8. PubMed ID: 8241229
[TBL] [Abstract][Full Text] [Related]
43. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens.
Di Munno O; Imbimbo B; Mazzantini M; Milani S; Occhipinti G; Pasero G
J Rheumatol; 1995 Aug; 22(8):1492-8. PubMed ID: 7473472
[TBL] [Abstract][Full Text] [Related]
44. Deflazacort in the treatment of uveitis: a comparative study versus prednisone.
Cerqueti Piera M; Saccà Sergio C; Allegri P; Ciurlo G; Zingirian M; Buscaglia S; Ciprandi G
Allergol Immunopathol (Madr); 1993; 21(3):107-10. PubMed ID: 8356936
[TBL] [Abstract][Full Text] [Related]
45. The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects.
Nielsen HK; Thomsen K; Eriksen EF; Charles P; Storm T; Mosekilde L
Bone Miner; 1988 Apr; 4(1):105-13. PubMed ID: 3263890
[TBL] [Abstract][Full Text] [Related]
46. Deflazacort.
Joshi N; Rajeshwari K
J Postgrad Med; 2009; 55(4):296-300. PubMed ID: 20083885
[TBL] [Abstract][Full Text] [Related]
47. Deflazacort in juvenile chronic arthritis.
Loftus JK; Reeve J; Hesp R; David J; Ansell BM; Woo PM
J Rheumatol Suppl; 1993 Apr; 37():40-2. PubMed ID: 8501751
[TBL] [Abstract][Full Text] [Related]
48. Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure.
Chan JC; Kodroff MB; Landwehr DM
Pediatrics; 1981 Oct; 68(4):559-71. PubMed ID: 6895662
[TBL] [Abstract][Full Text] [Related]
49. Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica.
Lund B; Egsmose C; Jørgensen S; Krogsgaard MR
Calcif Tissue Int; 1987 Dec; 41(6):316-20. PubMed ID: 3124940
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
Griggs RC; Miller JP; Greenberg CR; Fehlings DL; Pestronk A; Mendell JR; Moxley RT; King W; Kissel JT; Cwik V; Vanasse M; Florence JM; Pandya S; Dubow JS; Meyer JM
Neurology; 2016 Nov; 87(20):2123-2131. PubMed ID: 27566742
[TBL] [Abstract][Full Text] [Related]
51. Spinal and somatic growth in patients with juvenile chronic arthritis treated for up to 2 years with deflazacort.
David J; Loftus J; Hesp R; Ansell BM; Reeve J; Woo PM
Clin Exp Rheumatol; 1992; 10(6):621-4. PubMed ID: 1483317
[TBL] [Abstract][Full Text] [Related]
52. Comparative study of deflazacort, a new synthetic corticosteroid, and dexamethasone on the synthesis of collagen in different rat bone cell populations and rabbit articular chondrocytes.
Guenther HL; Felix R; Fleisch H
Calcif Tissue Int; 1984 Mar; 36(2):145-52. PubMed ID: 6430498
[TBL] [Abstract][Full Text] [Related]
53. Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Prednisone, deflazacort, and betamethasone.
Pagano G; Bruno A; Cavallo-Perin P; Cesco L; Imbimbo B
Arch Intern Med; 1989 May; 149(5):1098-101. PubMed ID: 2655543
[TBL] [Abstract][Full Text] [Related]
54. Vitamin D and parathyroid hormone status in children with the nephrotic syndrome and chronic mild glomerulonephritis.
Chesney RW; Hamstra A; Rose P; DeLuca HF
Int J Pediatr Nephrol; 1984 Mar; 5(1):1-4. PubMed ID: 6715110
[TBL] [Abstract][Full Text] [Related]
55. Effect of therapy with deflazacort on dyslipoproteinemia after pediatric renal transplantation.
Ferraris JR; Sorroche P; Legal S; Oyhamburu J; Brandi P; Pasqualini T
J Pediatr; 1998 Oct; 133(4):533-6. PubMed ID: 9787693
[TBL] [Abstract][Full Text] [Related]
56. Effect of growth hormone therapy on bone metabolism of growth hormone deficient children.
Stamoyannou L; Karachaliou F; Gioureli E; Voskaki E; Mengreli C; Bartsocas CS; Koutselinis A
Eur J Pediatr; 1997 Aug; 156(8):592-6. PubMed ID: 9266187
[TBL] [Abstract][Full Text] [Related]
57. Experience with deflazacort in children and adolescents after renal transplantation.
Schärer K; Feneberg R; Klaus G; Paschen C; Wüster C; Mehls O; Schaefer F
Pediatr Nephrol; 2000 Jun; 14(6):457-63. PubMed ID: 10872183
[TBL] [Abstract][Full Text] [Related]
58. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.
Singh DN; Krishnamurthy S; Kamalanathan SK; Harichandrakumar KT; Sivamurukan P
Paediatr Int Child Health; 2018 Nov; 38(4):251-260. PubMed ID: 30092157
[TBL] [Abstract][Full Text] [Related]
59. Clinical equivalence of a new glucocorticoid, deflazacort and prednisone in rheumatoid arthritis and S.L.E. patients.
Imbimbo B; Tuzi T; Porzio F; Schiavetti L
Adv Exp Med Biol; 1984; 171():241-56. PubMed ID: 6372394
[No Abstract] [Full Text] [Related]
60. Decreased bone density in severely handicapped children and adults, with reference to the influence of limited mobility and anticonvulsant medication.
Nishiyama S; Kuwahara T; Matsuda I
Eur J Pediatr; 1986 Feb; 144(5):457-63. PubMed ID: 3007152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
